Collaboration Deals in Pharmaceuticals 2019-2023
SUMMARY
Collaboration Deals in Pharmaceuticals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2019 to 2023Collaboration Deals in Pharmaceuticals provides a detailed understanding and analysis of how and why companies enter collaboration deals.
Fully revised and updated, the report provides details of collaboration deals from 2019 to 2023.
The report provides access to collaboration deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual collaboration contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of collaboration dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in collaboration as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of collaboration deals.
Chapter 4 provides a review of the leading collaboration deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active collaboration dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of collaboration deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the collaboration deal.
The deal directory includes a comprehensive listing of all collaboration deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in collaboration dealmaking since 2019.
In conclusion, this report provides everything a prospective dealmaker needs to know about collaboration alliances.
Key benefits
Collaboration Deals in Pharmaceuticals provides the reader with the following key benefits:
Collaboration Deals in Pharmaceuticals is intended to provide the reader with an in-depth understanding of the collaboration trends and structure of deals entered into by leading biopharma companies worldwide.
Collaboration Deals in Pharmaceuticals includes:
Collaboration Deals in Pharmaceuticals provides comprehensive access to available records for collaboration deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
BENEFITS
Collaboration Deals in Pharmaceuticals provides the reader with the following key benefits:
Collaboration Deals in Pharmaceuticals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2019 to 2023Collaboration Deals in Pharmaceuticals provides a detailed understanding and analysis of how and why companies enter collaboration deals.
Fully revised and updated, the report provides details of collaboration deals from 2019 to 2023.
The report provides access to collaboration deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual collaboration contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of collaboration dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in collaboration as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of collaboration deals.
Chapter 4 provides a review of the leading collaboration deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 25 most active collaboration dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of collaboration deals organized by company A-Z, therapy, technology and industry type signed and announced since 2019 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the collaboration deal.
The deal directory includes a comprehensive listing of all collaboration deals announced since 2019. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in collaboration dealmaking since 2019.
In conclusion, this report provides everything a prospective dealmaker needs to know about collaboration alliances.
Key benefits
Collaboration Deals in Pharmaceuticals provides the reader with the following key benefits:
- Understand deal trends since 2019
- Browse collaboration deals
- Benchmark analysis – identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Collaboration Deals in Pharmaceuticals is intended to provide the reader with an in-depth understanding of the collaboration trends and structure of deals entered into by leading biopharma companies worldwide.
Collaboration Deals in Pharmaceuticals includes:
- Trends in collaboration dealmaking in the biopharma industry
- Overview of collaboration deal structure
- Directory of collaboration deal records covering pharmaceutical and biotechnology
- The leading collaboration deals by value
- Most active collaboration dealmakers
- The leading collaboration partnering resources
- Company A-Z
- Headline value
- Therapeutic area
- Technology type
Collaboration Deals in Pharmaceuticals provides comprehensive access to available records for collaboration deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the rights granted or optioned?
- What rights are granted by the agreement?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are intellectual property rights handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What subcollaboration and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
BENEFITS
Collaboration Deals in Pharmaceuticals provides the reader with the following key benefits:
- Understand deal trends since 2019
- Browse pharmaceutical collaboration deals
- Benchmark analysis – identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
EXECUTIVE SUMMARY
CHAPTER 1 – INTRODUCTION
CHAPTER 2 – TRENDS IN COLLABORATION DEALMAKING
2.1. Introduction
2.2. Definition of collaboration deal
2.3. Trends in collaboration deals since 2019
2.3.1. Collaboration dealmaking by year, 2019-2023
2.3.2. Collaboration dealmaking by phase of development, 2019-2023
2.3.3. Collaboration dealmaking by industry sector, 2019-2023
2.3.4. Collaboration dealmaking by therapy area, 2019-2023
2.3.5. Collaboration dealmaking by technology type, 2019-2023
2.3.6. Collaboration dealmaking by most active company, 2019-2023
2.4. Reasons for entering into collaboration partnering deals
2.5. The future of collaboration deals
CHAPTER 3 – OVERVIEW OF COLLABORATION DEAL STRUCTURE
3.1. Introduction
3.2. Collaboration agreement structure
CHAPTER 4 – LEADING COLLABORATION DEALS
4.1. Introduction
4.2. Top collaboration deals by value
CHAPTER 5 – TOP 25 MOST ACTIVE COLLABORATION DEALMAKERS
5.1. Introduction
5.2. Top 25 most active collaboration dealmakers
CHAPTER 6 – COLLABORATION DEALS INCLUDING CONTRACTS DIRECTORY
6.1. Introduction
6.2. Collaboration deals with contracts 2019-2023
Deal directory
Deal directory – collaboration dealmaking by companies A-Z
Deal directory – collaboration dealmaking by therapy area
Deal directory – collaboration dealmaking by technology type
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of collaboration deal
Figure 2: Trends in collaboration deal announcements, 2019-2023
Figure 3: Collaboration deals signed at each phase of development, 2019-2023
Figure 4: Collaboration deals by industry sector, 2019-2023
Figure 5: Collaboration deals by therapy area, 2019-2023
Figure 6: Collaboration deals by technology type, 2019-2023
Figure 7: Top 25 most active collaboration dealmakers, 2019-2023
Figure 8: Top collaboration deals by value, 2019-2023
Figure 9: Most active collaboration dealmakers, 2019-2023
CHAPTER 1 – INTRODUCTION
CHAPTER 2 – TRENDS IN COLLABORATION DEALMAKING
2.1. Introduction
2.2. Definition of collaboration deal
2.3. Trends in collaboration deals since 2019
2.3.1. Collaboration dealmaking by year, 2019-2023
2.3.2. Collaboration dealmaking by phase of development, 2019-2023
2.3.3. Collaboration dealmaking by industry sector, 2019-2023
2.3.4. Collaboration dealmaking by therapy area, 2019-2023
2.3.5. Collaboration dealmaking by technology type, 2019-2023
2.3.6. Collaboration dealmaking by most active company, 2019-2023
2.4. Reasons for entering into collaboration partnering deals
2.5. The future of collaboration deals
CHAPTER 3 – OVERVIEW OF COLLABORATION DEAL STRUCTURE
3.1. Introduction
3.2. Collaboration agreement structure
CHAPTER 4 – LEADING COLLABORATION DEALS
4.1. Introduction
4.2. Top collaboration deals by value
CHAPTER 5 – TOP 25 MOST ACTIVE COLLABORATION DEALMAKERS
5.1. Introduction
5.2. Top 25 most active collaboration dealmakers
CHAPTER 6 – COLLABORATION DEALS INCLUDING CONTRACTS DIRECTORY
6.1. Introduction
6.2. Collaboration deals with contracts 2019-2023
Deal directory
Deal directory – collaboration dealmaking by companies A-Z
Deal directory – collaboration dealmaking by therapy area
Deal directory – collaboration dealmaking by technology type
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
TABLE OF FIGURES
Figure 1: Definition of collaboration deal
Figure 2: Trends in collaboration deal announcements, 2019-2023
Figure 3: Collaboration deals signed at each phase of development, 2019-2023
Figure 4: Collaboration deals by industry sector, 2019-2023
Figure 5: Collaboration deals by therapy area, 2019-2023
Figure 6: Collaboration deals by technology type, 2019-2023
Figure 7: Top 25 most active collaboration dealmakers, 2019-2023
Figure 8: Top collaboration deals by value, 2019-2023
Figure 9: Most active collaboration dealmakers, 2019-2023
